Synthesis and Anti-Diabetic Evaluation of 2-Phenyl-3H-quinazolin-4-one Derivatives
Authors:
- K. P. D. H. PathiranaKPK. P. D. H. Pathirana
- D. A. Upeka ChathuranganiD. A. Upeka Chathurangani
- Julian VladJulian Vlad
- D. M. W. S. DissanayakeDDD. M. W. S. Dissanayake
- Yasiru Vindula AlwisYAYasiru Vindula Alwis
- G. Mashooda JayahGJG. Mashooda Jayah
- K. P. S. S. PathiranaK. P. S. S. Pathirana
- Dinusha Nishani UdukalaDUDinusha Nishani Udukala
- Nishal M. EgodawaththaNENishal M. Egodawaththa
- Nasri NesnasNNNasri Nesnas
- Medha Jaimini GunaratnaMGMedha Jaimini Gunaratna
Open Access
- 16 August 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (8) , 1013
Abstract
Background/Objectives: Diabetes mellitus is a common endocrine disorder characterized by hyperglycemia, which is increasing steadily all over the world. Current medications are limited due to lower efficacy and side effects; therefore, the introduction of novel compounds is crucial to improve therapeutic outcomes for diabetic patients. The objective of this study was to synthesize and evaluate 2-phenyl-3H-quinazolin-4-one and its derivatives for the glucose uptake across the yeast cell membranes, alpha-amylase inhibition, and alpha-glucosidase inhibition in silico and in vitro. Methods: The synthesis of 2-phenyl-3H-quinazolin-4-one and its derivatives was carried out by oxidative cyclocondensation of 2-aminobenzamide (anthranilamide) with various benzaldehydes in the presence of aqueous iron (III) chloride. The synthesized compounds were characterized by melting point determination and spectroscopic techniques, including FTIR, NMR and HRMS. Results: In the glucose uptake by yeast assay, compound 3f had a lower 50% glucose uptake value of 24.02 ± 0.96 mM, compared with the standard drug metformin (25.99 ± 2.41 mM). The alpha-amylase inhibition bioassay showed that compound 3e exhibited very potent inhibition, with an IC50 of 0.43 ± 0.05 mM, compared with the standard drug acarbose (0.53 ± 0.21 mM). Compound 3l exhibited strong alpha-glucosidase inhibition, with an IC50 of 0.42 ± 0.10 mM, compared with the standard drug acarbose (0.29 ± 0.50 mM). Coclusions: These findings suggest the potential of synthesized 2-phenyl-3H-quinazolin-4-one derivatives, 3a–o, as promising candidates for managing diabetes mellitus. However, further studies are required to validate their efficacy and determine their mechanisms of action.Keywords
This publication has 39 references indexed in Scilit:
- Novel Quinazolinone Derivatives: Potential Synthetic Analogs for the Treatment of Glaucoma, Alzheimer's Disease and Diabetes MellitusChemistry & Biodiversity, 2023
- Ficus benghalensis promotes the glucose uptake- Evidence with in silico and in vitroJournal of Diabetes & Metabolic Disorders, 2022
- A review of alpha-glucosidase inhibitors from plants as potential candidates for the treatment of type-2 diabetesPhytochemistry Reviews, 2021
- α-Glucosidase and α-amylase inhibition, molecular modeling and pharmacokinetic studies of new quinazolinone-1,2,3-triazole-acetamide derivativesMedicinal Chemistry Research, 2021
- Synthetic heterocyclic candidates as promising α-glucosidase inhibitors: An overviewEuropean Journal of Medicinal Chemistry, 2019
- New indole based hybrid oxadiazole scaffolds with N-substituted acetamides: As potent anti-diabetic agentsBioorganic Chemistry, 2018
- Quinazolinone derivatives: Synthesis and comparison of inhibitory mechanisms on α-glucosidaseBioorganic & Medicinal Chemistry, 2017
- Small-Molecule Library Screening by Docking with PyRx2014
- General aspects of diabetes mellitus2014
- Alpha-Glucosidase Folding During Urea Denaturation: Enzyme Kinetics and Computational PredictionApplied Biochemistry and Biotechnology, 2009